Regulus Therapeutics Inc (RGLS) stock is down 16.89% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With RGLS Stock Today?
Regulus Therapeutics Inc (RGLS) stock is down -11.51% while the S&P 500 is higher by 0.24% as of 2:20 PM on Tuesday, Apr 13. RGLS has fallen -$0.16 from the previous closing price of $1.39 on volume of 801,224 shares. Over the past year the S&P 500 is higher by 49.84% while RGLS is higher by 156.25%. RGLS lost -$0.45 per share in the over the last 12 months.
To screen for more stocks like Regulus Therapeutics Inc click here.
More About Regulus Therapeutics Inc
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
Click Here to get the full Stock Score Report on Regulus Therapeutics Inc (RGLS) Stock.
